Enlicitide Decanoate

Generic Name: Enlicitide Decanoate

Clinical Trials

A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)

Phase 1

Recruiting

Conditions: Healthy
Renal Impairment

Interventions: Drug: Enlicitide

First Posted Date: 2024-10-16

Last Posted Date: 2025-03-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 24

Registration Number: NCT06643377

Locations: 🇺🇸
Nature Coast Clinical Research - Inverness ( Site 0002), Inverness, Florida, United States
🇺🇸
Genesis Clinical Research, LLC ( Site 0001), Tampa, Florida, United States
🇺🇸
Velocity Clinical Research, Hallandale Beach ( Site 0006), Hallandale Beach, Florida, United States

and more 2 locations

A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Levothyroxine
Drug: Enlicitide Decanoate

First Posted Date: 2024-10-03

Last Posted Date: 2024-10-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 28

Registration Number: NCT06625814

Locations: 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States

A Clincal Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Enlicitide

First Posted Date: 2024-09-24

Last Posted Date: 2025-02-07

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 20

Registration Number: NCT06609512

Locations: 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States

A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Enlicitide
Drug: Digoxin

First Posted Date: 2024-09-19

Last Posted Date: 2024-11-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 24

Registration Number: NCT06597760

Locations: 🇺🇸
Celerion ( Site 0001), Lincoln, Nebraska, United States

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

Phase 1

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: MK-0616

First Posted Date: 2024-09-12

Last Posted Date: 2024-09-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 24

Registration Number: NCT06592339

Locations: 🇺🇸
QPS-MRA, LLC-Early Phase, South Miami, Florida, United States

A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)

Phase 1

Active, not recruiting

Conditions: Hepatic Insufficiency
Hepatic Impairment

Interventions: Drug: Enlicitide

First Posted Date: 2024-08-28

Last Posted Date: 2025-04-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 40

Registration Number: NCT06575959

Locations: 🇺🇸
Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States
🇺🇸
The Texas Liver Institute ( Site 0001), San Antonio, Texas, United States

Open-label Extension Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

Phase 3

Recruiting

Conditions: Hypercholesterolemia

Interventions: Drug: Enlicitide Decanoate

First Posted Date: 2024-07-09

Last Posted Date: 2025-05-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 3000

Registration Number: NCT06492291

Locations: 🇮🇱
Rambam Health Care Campus ( Site 1742), Haifa, Israel
🇺🇸
Alliance for Multispecialty Research, LLC ( Site 0027), Daphne, Alabama, United States
🇺🇸
G&L Research ( Site 0035), Foley, Alabama, United States

and more 219 locations

A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn

Phase 3

Active, not recruiting

Conditions: Hypercholesterolemia

Interventions: Drug: Ezetimibe
Drug: Bempedoic Acid
Drug: Enlicitide Decanoate
Other: Placebo for Ezetimibe
Other: Placebo for Enlicitide Decanoate
Other: Placebo for Bempedoic Acid

First Posted Date: 2024-06-10

Last Posted Date: 2025-02-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 301

Registration Number: NCT06450366

Locations: 🇺🇸
Clinical Trials Research ( Site 1509), Lincoln, California, United States
🇺🇸
Velocity Clinical Research Rockville ( Site 1503), Rockville, Maryland, United States
🇺🇸
Rainier Clinical Research Center ( Site 1502), Renton, Washington, United States

and more 32 locations

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

Phase 3

Recruiting

Conditions: Arteriosclerosis
Hypercholesterolaemia

Interventions: Drug: Enlicitide Decanoate
Drug: Placebo

First Posted Date: 2023-08-24

Last Posted Date: 2025-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 14550

Registration Number: NCT06008756

Locations: 🇺🇸
Advanced Cardiovascular - Alexander City ( Site 0156), Alexander City, Alabama, United States
🇺🇸
Central Research Associates ( Site 0118), Birmingham, Alabama, United States
🇺🇸
St. Vincent's Birmingham Hospital ( Site 0181), Birmingham, Alabama, United States

and more 662 locations

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

Phase 3

Active, not recruiting

Conditions: Hypercholesterolemia
Familial Hypercholesterolemia

Interventions: Drug: Enlicitide Decanoate
Drug: Placebo

First Posted Date: 2023-07-19

Last Posted Date: 2024-11-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 2760

Registration Number: NCT05952856

Locations: 🇺🇸
Midwest Institute For Clinical Research ( Site 0059), Indianapolis, Indiana, United States
🇺🇸
Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0111), Houston, Texas, United States
🇹🇷
Ege Universitesi Hastanesi-Cardilogy Department ( Site 2502), Bornova, Izmir, Turkey

and more 165 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy